# US 10,933,073 B2 · Compositions and methods comprising a psilocybin derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,933,073 B2
- Document ID: US10933073B2
- Status: Granted
- Kind: B2
- Application number: 15/893,562
- Filed: 2018-02-09
- Published: 2018-08-09
- Granted: 2021-03-02
- Earliest claimed: 2017-02-09
- Assignees: Caamtech, Inc.
- Applicants: CaaMTech, LLC
- Inventors: Andrew R. Chadeayne
- Web page: https://patentgrep.com/patent/US10933073B2

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.

## Claims

### Claim 1

A dosage formulation comprising:
a purified psilocybin derivative selected from the group consisting of [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, and 4-hydroxy-N,N,N-trimethyltryptamine; and
a purified cannabinoid selected from the group consisting of Cannabichromene (CBC), Cannabichromenic acid (CBCA), Cannabichromevarin (CBCV), Cannabichromevarinic acid (CBCVA), Cannabidiol (CBD), Cannabidiolic acid (CBDA), Cannabidivarin (CBDV), Cannabidivarinic acid (CBDVA), Cannabigerol (CBG), Cannabigerolic acid (CBGA), Cannabigerovarin (CBGV), Cannabigerovarinic acid (CBGVA), Delta-9-tetrahydrocannabinol (THC), Delta-9-tetrahydrocannabinolic acid A (THCA-A), Delta-9-tetrahydrocannabinolic acid B (THCA-B), Delta-9-tetrahydrocannabivarin (THCV), Delta-9-tetrahydrocannabivarinic acid (THCVA).

### Claim 2 (depends on 1)

A dosage composition of claim 1, wherein the purified cannabinoid is selected from the group consisting of Delta-9-tetrahydrocannabinol (THC), Cannabichromene (CBC), Cannabidiol (CBD), and Cannabigerol (CBG).

### Claim 3 (depends on 2)

A dosage composition of claim 2 wherein the purified cannabinoid is Cannabichromene (CBC).

### Claim 4 (depends on 1)

A dosage composition of claim 1, wherein molar ratio of the purified psilocybin derivative to the purified cannabinoid is about 100:1 to about 1:100.

### Claim 5 (depends on 4)

A dosage composition of claim 4, wherein molar ratio of the purified psilocybin derivative to the purified cannabinoid is about 25:1 to about 1:25.

### Claim 6 (depends on 5)

A dosage composition of claim 5, wherein molar ratio of the purified psilocybin derivative to the purified cannabinoid is about 10:1 to about 1:10.

### Claim 7 (depends on 6)

A dosage composition of claim 6, wherein molar ratio of the purified psilocybin derivative to the purified cannabinoid is about 5:1 to about 1:5.

### Claim 8 (depends on 2)

A dosage composition of claim 2, wherein the purified psilocybin derivative is [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

### Claim 9 (depends on 2)

A dosage composition of claim 2, wherein the purified psilocybin derivative is 4-hydroxy-N-methyltryptamine.

### Claim 10 (depends on 2)

A dosage composition of claim 2, wherein the purified psilocybin derivative is [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

### Claim 11 (depends on 2)

A dosage composition of claim 2, wherein the purified psilocybin derivative is 4-hydroxytryptamine.

### Claim 12 (depends on 2)

A dosage composition of claim 2, wherein the purified psilocybin derivative is [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

### Claim 13 (depends on 2)

A dosage composition of claim 2, wherein the purified psilocybin derivative is 4-hydroxy-N,N,N-trimethyltryptamine.
